Market closed

Corvus Pharmaceuticals/$CRVS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Corvus Pharmaceuticals

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Ticker

$CRVS
Trading on

Industry

Biotechnology

Employees

28

CRVS Metrics

BasicAdvanced
$598M
Market cap
-
P/E ratio
-$0.44
EPS
1.10
Beta
-
Dividend rate
$598M
1.1
$9.28
$1.23
847K
3.619
3.552
1.366
1.366
-23.83%
-44.91%
11.67
11.67
-23.27
-47.71%
36.99%

What the Analysts think about CRVS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.

CRVS Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CRVS Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRVS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Corvus Pharmaceuticals stock?

Corvus Pharmaceuticals (CRVS) has a market cap of $598M as of November 13, 2024.

What is the P/E ratio for Corvus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of November 13, 2024.

Does Corvus Pharmaceuticals stock pay dividends?

No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next Corvus Pharmaceuticals dividend payment date?

Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.

What is the beta indicator for Corvus Pharmaceuticals?

Corvus Pharmaceuticals (CRVS) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.